457 related articles for article (PubMed ID: 18780830)
1. Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist.
Iglarz M; Binkert C; Morrison K; Fischli W; Gatfield J; Treiber A; Weller T; Bolli MH; Boss C; Buchmann S; Capeleto B; Hess P; Qiu C; Clozel M
J Pharmacol Exp Ther; 2008 Dec; 327(3):736-45. PubMed ID: 18780830
[TBL] [Abstract][Full Text] [Related]
2. Macitentan, a tissue-targeting endothelin receptor antagonist for the potential oral treatment of pulmonary arterial hypertension and idiopathic pulmonary fibrosis.
Raja SG
Curr Opin Investig Drugs; 2010 Sep; 11(9):1066-73. PubMed ID: 20730702
[TBL] [Abstract][Full Text] [Related]
3. The discovery of N-[5-(4-bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N'-propylsulfamide (Macitentan), an orally active, potent dual endothelin receptor antagonist.
Bolli MH; Boss C; Binkert C; Buchmann S; Bur D; Hess P; Iglarz M; Meyer S; Rein J; Rey M; Treiber A; Clozel M; Fischli W; Weller T
J Med Chem; 2012 Sep; 55(17):7849-61. PubMed ID: 22862294
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological profile of T-0201, a highly potent and orally active endothelin receptor antagonist.
Hoshino T; Yamauchi R; Kikkawa K; Yabana H; Murata S
J Pharmacol Exp Ther; 1998 Aug; 286(2):643-9. PubMed ID: 9694915
[TBL] [Abstract][Full Text] [Related]
5. Novel dual endothelin receptor antagonist macitentan reverses severe pulmonary arterial hypertension in rats.
Kunita-Takanezawa M; Abe K; Hirooka Y; Kuwabara Y; Hirano K; Oka M; Sunagawa K
J Cardiovasc Pharmacol; 2014 Nov; 64(5):473-80. PubMed ID: 25084082
[TBL] [Abstract][Full Text] [Related]
6. Ro 61-1790, a new hydrosoluble endothelin antagonist: general pharmacology and effects on experimental cerebral vasospasm.
Roux S; Breu V; Giller T; Neidhart W; Ramuz H; Coassolo P; Clozel JP; Clozel M
J Pharmacol Exp Ther; 1997 Dec; 283(3):1110-8. PubMed ID: 9399983
[TBL] [Abstract][Full Text] [Related]
7. Renal, retinal and cardiac changes in type 2 diabetes are attenuated by macitentan, a dual endothelin receptor antagonist.
Sen S; Chen S; Feng B; Iglarz M; Chakrabarti S
Life Sci; 2012 Oct; 91(13-14):658-68. PubMed ID: 22525377
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological profile of ZD1611, a novel, orally active endothelin ETA receptor antagonist.
Wilson C; Hunt SJ; Tang E; Wright N; Kelly E; Palmer S; Heys C; Mellor S; James R; Bialecki R
J Pharmacol Exp Ther; 1999 Sep; 290(3):1085-91. PubMed ID: 10454481
[TBL] [Abstract][Full Text] [Related]
9. Safety, tolerability, pharmacokinetics, and pharmacodynamics of macitentan, an endothelin receptor antagonist, in an ascending multiple-dose study in healthy subjects.
Sidharta PN; van Giersbergen PL; Dingemanse J
J Clin Pharmacol; 2013 Nov; 53(11):1131-8. PubMed ID: 23900878
[TBL] [Abstract][Full Text] [Related]
10. Comparison of pharmacological activity of macitentan and bosentan in preclinical models of systemic and pulmonary hypertension.
Iglarz M; Bossu A; Wanner D; Bortolamiol C; Rey M; Hess P; Clozel M
Life Sci; 2014 Nov; 118(2):333-9. PubMed ID: 24582812
[TBL] [Abstract][Full Text] [Related]
11. Discovery and synthesis of (S)-3-[2-(3,4-dimethoxyphenyl)ethoxy]-2- (4,6-dimethylpyrimidin-2-yloxy)-3,3-diphenylpropionic acid (LU 302872), a novel orally active mixed ET(A)/ET(B) receptor antagonist.
Amberg W; Hergenröder S; Hillen H; Jansen R; Kettschau G; Kling A; Klinge D; Raschack M; Riechers H; Unger L
J Med Chem; 1999 Aug; 42(16):3026-32. PubMed ID: 10447946
[TBL] [Abstract][Full Text] [Related]
12. Endothelin-1-induced pulmonary vasoreactivity is regulated by ET(A) and ET(B) receptor interactions.
Sauvageau S; Thorin E; Caron A; Dupuis J
J Vasc Res; 2007; 44(5):375-81. PubMed ID: 17495482
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist.
Clozel M; Breu V; Gray GA; Kalina B; Löffler BM; Burri K; Cassal JM; Hirth G; Müller M; Neidhart W
J Pharmacol Exp Ther; 1994 Jul; 270(1):228-35. PubMed ID: 8035319
[TBL] [Abstract][Full Text] [Related]
14. The orally active nonpeptide selective endothelin ETA receptor antagonist YM598 prevents and reverses the development of pulmonary hypertension in monocrotaline-treated rats.
Yuyama H; Fujimori A; Sanagi M; Koakutsu A; Sudoh K; Sasamata M; Miyata K
Eur J Pharmacol; 2004 Aug; 496(1-3):129-39. PubMed ID: 15288584
[TBL] [Abstract][Full Text] [Related]
15. Rescue of pulmonary hypertension with an oral sulfonamide antibiotic sulfisoxazole by endothelin receptor antagonistic actions.
Uchino T; Sanyal SN; Yamabe M; Kaku T; Takebayashi S; Shimaoka T; Shimada T; Noguchi T; Ono K
Hypertens Res; 2008 Sep; 31(9):1781-90. PubMed ID: 18971557
[TBL] [Abstract][Full Text] [Related]
16. Endothelin receptor antagonist reverses decreased NO system in the kidney in vivo during exercise.
Maeda S; Miyauchi T; Iemitsu M; Tanabe T; Goto K; Yamaguchi I; Matsuda M
Am J Physiol Endocrinol Metab; 2004 Apr; 286(4):E609-14. PubMed ID: 14665447
[TBL] [Abstract][Full Text] [Related]
17. Efficacy, safety and clinical pharmacology of macitentan in comparison to other endothelin receptor antagonists in the treatment of pulmonary arterial hypertension.
Dingemanse J; Sidharta PN; Maddrey WC; Rubin LJ; Mickail H
Expert Opin Drug Saf; 2014 Mar; 13(3):391-405. PubMed ID: 24261583
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of endothelin-1-induced pulmonary vasoconstriction following myocardial infarction.
Sauvageau S; Thorin E; Caron A; Dupuis J
Exp Biol Med (Maywood); 2006 Jun; 231(6):840-6. PubMed ID: 16741009
[TBL] [Abstract][Full Text] [Related]
19. Macitentan slows down the dermal fibrotic process in systemic sclerosis: in vitro findings.
Corallo C; Pecetti G; Iglarz M; Volpi N; Franci D; Montella A; D' Onofrio F; Nuti R; Giordano N
J Biol Regul Homeost Agents; 2013; 27(2):455-62. PubMed ID: 23830395
[TBL] [Abstract][Full Text] [Related]
20. CPU0213, a non-selective ETA/ETB receptor antagonist, improves pulmonary arteriolar remodeling of monocrotaline-induced pulmonary hypertension in rats.
Cui B; Cheng YS; Dai DZ; Li N; Zhang TT; Dai Y
Clin Exp Pharmacol Physiol; 2009 Feb; 36(2):169-75. PubMed ID: 18986320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
